Organisation paid for research Program year 2025 Source: CMS Open Payments

Joslin Diabetes Center

Neither a doctor nor a teaching hospital

Research payments

$3,186,933

1,721 payments

Through program year 2025, Joslin Diabetes Center is reported as receiving $3,186,933 in research payments, across 1,721 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$566,944	165
2024	Research	$168,688	109
2023	Research	$498,359	499
2022	Research	$762,455	327
2021	Research	$332,136	130
2020	Research	$232,422	172
2019	Research	$625,928	319

Breakdown

Who paid Research payments · program years 2019–2025

Insulet Corporation $789,005 33 payments
Novo Nordisk AS $715,931 1,251 payments
Recordati_Rare_Diseases_Inc. $365,793 6 payments
Bayer HealthCare Pharmaceuticals Inc. $340,501 180 payments
Dexcom, Inc. $184,273 13 payments
Tandem Diabetes Care, Inc. $173,930 1 payment
Sequel Med Tech, LLC $159,701 148 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $159,086 11 payments
AstraZeneca UK Limited $100,869 7 payments
Medtronic, Inc. $51,210 8 payments

Studies the money was for Research payments · program years 2019–2025

Evaluating the Safety and Effectiveness of the Omnipod HorizonAutomated Glucose Control System in Children with Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort $593,006 19 payments
Pas576 $365,793 6 payments
Nn9535-4352 $284,988 625 payments
BAY94-8862 ph 3 conventional in diabetic nephropathy $270,218 130 payments
Control-IQ 2.0 Feasibility Study #2: Use of Control-IQ Technology 2.0 in Adults, Children and Preschoolers with Type 1 Diabetes $173,930 1 payment
52 wks Eff. & Saf. Ph III in Paediatrics $164,549 33 payments
Continuous Glucose Monitoring (CGM) Use to Assess Hypoglycemia and Reducing Unnecessary Patient Contact With Older Adults in Long Term Care (LTC) Facilities $160,376 7 payments
Innovative Automated Insulin Delivery System for T2D $159,701 148 payments
Nn9535-4801 $149,215 495 payments
Safety and Efficacy of the OmnipodTM 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes $119,321 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.